5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma

Patrick Loehrer, Diane Harry, Rowan T. Chlebowski

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

From January, 1985, through January, 1987, 165 patients with advanced gastric cancer were randomized to receive epirubicin (E) alone (90 mg/m2 day 1), 5-Fluorouracil (5-FU) alone (500 mg/m2 days 1-5), or the combination of E (90 mg/m2 day 1) and 5-FU (400 mg/m2 days 1-5). Courses were repeated every four weeks. Patients were stratified by extent (locally advanced vs. metastatic), evaluability (measurable vs. non-measurable) and by history of prior radiotherapy (yes vs. no). Randomization to single arm epirubicin was stopped after 26 patients were enrolled. Objective responses occurred in only 1/16 (6%) of the patients treated with E alone, 1/40 (5%) with 5-FU alone and 4/33 (12%) with both 5-FU and E. There were no significant differences in all eligible patients with respect to time to progression or overall survival in the three treatment arms. Toxicity was primarily hematologic and more pronounced in the combination arm. Neither 5-FU alone, epirubicin alone, or the combination have a major impact in the treatment of gastric carcinoma.

Original languageEnglish
Pages (from-to)57-63
Number of pages7
JournalInvestigational New Drugs
Volume12
Issue number1
DOIs
StatePublished - Mar 1994

Fingerprint

Epirubicin
Fluorouracil
Stomach
Carcinoma
Random Allocation
Stomach Neoplasms
Radiotherapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma. / Loehrer, Patrick; Harry, Diane; Chlebowski, Rowan T.

In: Investigational New Drugs, Vol. 12, No. 1, 03.1994, p. 57-63.

Research output: Contribution to journalArticle

@article{c299af7e4a314500930346c89bf526a0,
title = "5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma",
abstract = "From January, 1985, through January, 1987, 165 patients with advanced gastric cancer were randomized to receive epirubicin (E) alone (90 mg/m2 day 1), 5-Fluorouracil (5-FU) alone (500 mg/m2 days 1-5), or the combination of E (90 mg/m2 day 1) and 5-FU (400 mg/m2 days 1-5). Courses were repeated every four weeks. Patients were stratified by extent (locally advanced vs. metastatic), evaluability (measurable vs. non-measurable) and by history of prior radiotherapy (yes vs. no). Randomization to single arm epirubicin was stopped after 26 patients were enrolled. Objective responses occurred in only 1/16 (6{\%}) of the patients treated with E alone, 1/40 (5{\%}) with 5-FU alone and 4/33 (12{\%}) with both 5-FU and E. There were no significant differences in all eligible patients with respect to time to progression or overall survival in the three treatment arms. Toxicity was primarily hematologic and more pronounced in the combination arm. Neither 5-FU alone, epirubicin alone, or the combination have a major impact in the treatment of gastric carcinoma.",
author = "Patrick Loehrer and Diane Harry and Chlebowski, {Rowan T.}",
year = "1994",
month = "3",
doi = "10.1007/BF00873238",
language = "English",
volume = "12",
pages = "57--63",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - 5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma

AU - Loehrer, Patrick

AU - Harry, Diane

AU - Chlebowski, Rowan T.

PY - 1994/3

Y1 - 1994/3

N2 - From January, 1985, through January, 1987, 165 patients with advanced gastric cancer were randomized to receive epirubicin (E) alone (90 mg/m2 day 1), 5-Fluorouracil (5-FU) alone (500 mg/m2 days 1-5), or the combination of E (90 mg/m2 day 1) and 5-FU (400 mg/m2 days 1-5). Courses were repeated every four weeks. Patients were stratified by extent (locally advanced vs. metastatic), evaluability (measurable vs. non-measurable) and by history of prior radiotherapy (yes vs. no). Randomization to single arm epirubicin was stopped after 26 patients were enrolled. Objective responses occurred in only 1/16 (6%) of the patients treated with E alone, 1/40 (5%) with 5-FU alone and 4/33 (12%) with both 5-FU and E. There were no significant differences in all eligible patients with respect to time to progression or overall survival in the three treatment arms. Toxicity was primarily hematologic and more pronounced in the combination arm. Neither 5-FU alone, epirubicin alone, or the combination have a major impact in the treatment of gastric carcinoma.

AB - From January, 1985, through January, 1987, 165 patients with advanced gastric cancer were randomized to receive epirubicin (E) alone (90 mg/m2 day 1), 5-Fluorouracil (5-FU) alone (500 mg/m2 days 1-5), or the combination of E (90 mg/m2 day 1) and 5-FU (400 mg/m2 days 1-5). Courses were repeated every four weeks. Patients were stratified by extent (locally advanced vs. metastatic), evaluability (measurable vs. non-measurable) and by history of prior radiotherapy (yes vs. no). Randomization to single arm epirubicin was stopped after 26 patients were enrolled. Objective responses occurred in only 1/16 (6%) of the patients treated with E alone, 1/40 (5%) with 5-FU alone and 4/33 (12%) with both 5-FU and E. There were no significant differences in all eligible patients with respect to time to progression or overall survival in the three treatment arms. Toxicity was primarily hematologic and more pronounced in the combination arm. Neither 5-FU alone, epirubicin alone, or the combination have a major impact in the treatment of gastric carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0028341613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028341613&partnerID=8YFLogxK

U2 - 10.1007/BF00873238

DO - 10.1007/BF00873238

M3 - Article

C2 - 7960608

AN - SCOPUS:0028341613

VL - 12

SP - 57

EP - 63

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -